跳至主要内容
临床试验/CTRI/2023/06/053828
CTRI/2023/06/053828招募中Unknown

A Cross-sectional study to assess the Clinical Impact, Safety and Utilization of Triple Drug Fixed-dose Combination of GLImepiride, MEtformin and VOGlibose in the Management of Type 2 Diabetes Mellitus (GLIMEVOG Study)

Torrent Pharmaceuticals Ltd,0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1) Uncontrolled T2DM >= 7% HbA1c, FBG > 100 mg/dL & PPBG >= 200 mg/dL
  • 2) Patients of either sex, above 18 years of age with T2DM and who had received treatment with FDC of glimepiride, metformin sustained release (SR) and voglibose of any strength

排除标准

  • 1) Patients who had incomplete data or any condition that according to the discretion of the investigator indicated that the patient is not suitable for the study were excluded. Duration

研究者

发起方
Torrent Pharmaceuticals Ltd,

相似试验